Question 1

What are the side effects of IGF-1 LR3?

Accepted Answer

Separate the vial from the pharmacy before reading any of this, because the documented adverse events belong almost entirely to the pharmacy preparation. IGF-1 LR3 (Long R3 IGF-1) is a modified version of the hormone sold online, and no study among the research behind this page administered it to a person and recorded what followed. What exists instead is a description of a whole category. A 2026 review groups IGF-1 LR3 with other unregulated peptides aimed at the growth hormone axis, and reports adverse effects spanning hormonal and metabolic disturbance, fluid retention, muscular and joint symptoms, and reactions at the injection site. Read what that actually is. It is guidance written for doctors, covering symptoms seen across a whole family of compounds that people inject on their own. It is not the same thing as a tally taken from people given this one compound, and that tally has not been published.

Question 2

What adverse effects were recorded with the approved medicine?

Accepted Answer

The approved medicine is mecasermin, a lab-made copy of human IGF-1, given to children who cannot make enough of their own. A 2009 review covering nearly twenty years of use names hypoglycaemia as the most frequent side effect, readily controlled by giving the injection with meals. Hypoglycaemia is blood sugar that has fallen too low. The same review enumerates the other common ones. Lymphoid tissue enlarged, which sometimes required removal of the tonsils or adenoids, body fat accumulated, and the features of the face became coarser. A 2015 clinical review is blunter about the balance of advantage. It reports that few young or adult patients will benefit from mecasermin, given the number of adverse effects found. That sentence is about patients short of the hormone, which is not the same group as an adult who already makes a normal amount of it.

Question 3

Why does hypoglycaemia come up first?

Accepted Answer

IGF-1 looks enough like insulin to act like it, and two reviews describe each side of that. A 2007 review reports that adverse events, particularly hypoglycaemia, have been reported with unbound recombinant human IGF-1. A 2009 review adds that the same molecule has worked as an insulin-sensitising agent in patients with severe insulin resistance. That is the useful face of one property. A molecule that can drop blood sugar on purpose in one patient can drop it too far in the next. This is why the rule about meals is on the record at all. It is a handling rule for an approved injection given under close watch, written for children with a diagnosed shortfall rather than for an adult with an unlabelled vial.

Question 4

How much human safety evidence is there?

Accepted Answer

Count the people and the answer shrinks fast. Outside growth failure the trials are very small. A phase I open-label trial of mecasermin in children with Rett syndrome analysed nine participants, and a later randomised phase II trial did not show significant improvements in its primary outcomes. For severe insulin resistance, a 2018 case report puts the whole world literature at more than 30 treated patients. A 2025 systematic review of the Rett syndrome work reports that autonomic control and behavioural outcomes have been inconsistent across those trials, and calls for larger and better designed studies. So the human record comes to a few hundred people, nearly all of them children with a rare diagnosis, watched by specialists. It records what happened in a clinic to patients short of the hormone, rather than sampling what happens to anyone else.

Question 5

Does IGF-1 affect the liver?

Accepted Answer

This question usually arrives pointing in the wrong direction. The liver is where the body generates most of its own IGF-1, because growth hormone operates by stimulating IGF-1 synthesis in the liver, so a blood measurement is partly a reading of how that organ is performing. Travelling in the opposite direction, no study among the research behind this page reports liver enzymes, imaging or any other hepatic measurement in a patient administered IGF-1. The same 2009 review lists chronic liver disease among the conditions considered or trialled for it, which is the original question again rather than the one being asked. So the honest answer divides in two. The liver is central to how the hormone is generated, and the consequence of an injected version for that organ is unmeasured among the research behind this page rather than measured and found unremarkable.

Question 6

Is there a cancer concern with IGF-1?

Accepted Answer

There is a concern on the record, and it deserves careful reading. A 2009 review states that the anti-apoptotic properties of IGF-1 are implicated in cancer pathogenesis, and describes that as a concern for long-term therapy. Anti-apoptotic means the molecule prevents cells from dying on schedule. A 2026 review makes a comparable point about the unregulated market, describing mitogenic concerns that are biologically plausible but unproven. Mitogenic means prompting cells to divide, and there is a direct measurement of precisely that. In culture, IGF-1 LR3 increased uptake of a marker of cell division three- to five-fold in vitro. Now notice what sits between those two statements. A mechanism in a dish alongside a caution in a review is not the same thing as a measured incidence of cancer in people administered it, and no such figure appears among the research behind this page.

Question 7

What did the FDA adverse event reports show?

Accepted Answer

A 2025 analysis came at the question from a different direction. It read what clinicians and patients had already submitted to the FDA adverse event reporting system between 2004 and 2024, and counted 529 reports of precocious puberty attributed to a medicine. Precocious puberty means puberty arriving unusually early. Mecasermin sits high on that list. The medicines with the highest reporting odds ratios were mitotane at 220.35, mecasermin at 145.42, and clomifene at 141.35. A reporting odds ratio compares how often a symptom turns up with one medicine against how often it turns up with the rest. Read the limit into it. These are reports people chose to submit rather than a trial with a control group, and the authors note that medicines associated this way with precocious puberty are not listed as risk factors in labelling. A high ratio marks a question worth asking rather than a risk anyone has measured.

Question 8

Why did the diabetes trials stop?

Accepted Answer

Because of what might happen to the eyes. A 2009 review reports that although the insulin-sensitising effect may benefit both type 1 and type 2 diabetes, there are no ongoing clinical trials, because of concern about the risk of retinopathy and other complications. Retinopathy is damage to the small blood vessels at the back of the eye. That is one of the few places in this record where a line of research was halted over a safety question rather than over money or interest. It is also a concern about a likely mechanism rather than a counted rate of damage in patients. The same review concludes by judging mecasermin unlikely to prove useful beyond the orphan indications of severe insulin resistance and growth hormone insensitivity. An orphan indication is a condition rare enough to carry special status, and a reviewer narrowing the field that far is making a safety statement of a kind.

Question 9

What is the most serious outcome on record?

Accepted Answer

A 2018 case report follows a boy with Donohue syndrome, a severe inherited form of insulin resistance. Twice-daily injections proved unsatisfactory, and a continuous pump improved weight development and diabetes control in this patient, with a marker of long-term blood sugar falling from 10 to 7.6 per cent. He died at 22 months of age, during the course of a respiratory infection. The same report observes that the majority of children with this syndrome die within the first two years of life, which is the context that death has to be interpreted in. Attributing it to the injection would be wrong, and so would omitting it altogether. It is the most serious individual event in the human record behind this page, and it occurred in a child whose underlying condition was itself usually fatal inside that same interval.

Question 10

Who was in the studies behind this record?

Accepted Answer

Almost entirely children with a diagnosed deficiency, and the entry criterion is drawn tightly. A 2014 review sets it at a baseline IGF-1 score at or below minus three standard deviations, combined with a height score at or below minus three, in a child whose growth hormone is normal or elevated. A Canadian reimbursement review establishes the identical boundary from the funding side. It recommends coverage only for patients at least 2 years of age, carrying a confirmed diagnosis, whose growth plates have not yet closed. That is the population the adverse-effect record describes. An adult with a normal IGF-1 concentration, injecting an unlabelled vial to add muscle, falls outside every entry criterion in it. The record does not tell you what happens to that adult. It tells you what happened to patients carrying the opposite problem.

Question 11

What have regulators actually said about IGF-1?

Accepted Answer

Three statements, and each one is narrower than it looks. Mecasermin is approved in the United States for long-term use in growth failure in children with severe primary IGF-1 deficiency, and in the European Union for children and teenagers with the same severe shortfall. A 2026 review states the other half plainly. There is an absence of regulatory approval for physique or performance indications, and the review places IGF-1 LR3 among unregulated peptides marketed as research compounds. That is a boundary around what was approved rather than a verdict on legality, and the two get confused constantly. Nothing among the research behind this page says whether buying or holding IGF-1 LR3 is lawful where a reader lives, and a page that filled that in would be guessing.

Question 12

What is known about the contents of an unregulated vial?

Accepted Answer

Very little, and the review that raises it says so outright. A 2026 review describes uncertainty surrounding product composition, dose and stacking practices in unregulated supply chains, and builds its advice to doctors around that uncertainty rather than around any known list of contaminants. What the production literature shows is how the molecule is made properly. A 2023 paper made both IGF-1 and IGF-1 LR3 in a yeast system, fusing each one to an enzyme, then purified them and tested whether they still worked on cells. That is a lab process with its own purification steps and its own checks. A vial bought online carries a record of none of them, and no analysis among the research behind this page has measured the identity, the strength or the purity of material sold that way.

Question 13

What is documented about IGF-1 with insulin, or with food?

Accepted Answer

The interactions on the record are the two obvious ones, and both return to blood sugar. Food comes first, because hypoglycaemia is described as readily controlled by administration with meals, which makes a meal part of how the approved medicine is delivered at all. Insulin is the other. In the case report above, IGF-1 was delivered through an insulin pump to a child already being managed for diabetes, so a hospital team was handling the two of them in combination. Beyond those two, the interaction column is empty rather than reassuring. No study among the research behind this page administered IGF-1 alongside a named prescription medicine and reported the consequence, which is a different statement from establishing that nothing happens.

Question 14

Does the binding-protein version carry a different risk?

Accepted Answer

It was constructed to. Within the body, IGF-1 circulates bound to a carrier called binding protein 3, which regulates how much of it reaches the tissues. Mecasermin rinfabate combines the two of them in a single injection. A 2008 review states that this version was developed to prolong the half-life of IGF-1 and diminish side effects. The follow-up is the useful part, because the same review reports that the side effect profile appears similar to that of unbound IGF-1. A 2006 review is marginally more positive, noting fewer reports of adverse events, including hypoglycaemia, when it was administered to patients with diabetes. So a design aimed squarely at one documented harm produced a profile that still reads much like the original. A modification intended to address a side effect is not the same as a modification that eliminated it.

Question 15

How long has anyone been monitored on it?

Accepted Answer

Longer than you might expect, and within only one population. The investigation behind the approval followed 76 children, with a mean duration of therapy of 4.4 years and a range extending from under a month to 12.5 years. A smaller 2023 study tracked children with IGF-1 deficiency through 4 to 5 years of treatment while measuring stem cell populations circulating in their blood. A separate group in the same review was followed for 6.5 to 7.5 years, by which point the mean increase in height score was 1.4 standard deviations. Those are substantial intervals, and all of them are intervals in growing children under specialist supervision. Years of exposure in that population is not the same evidence as years of exposure in an adult, and the second has not been published.

IGF-1 side effects and safety data